KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Veronica Conca, Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Giovanni Randon, Daniele Lavacchi, Carmelo Pozzo, Federica Marmorino, Francesca Bergamo, Emiliano Tamburini, Alessandro Passardi, Roberta Fazio, Sabina Murgioni, Beatrice Borelli, Angela Buonadonna, Marco Maria Germani, Vincenzo Formica, Martina Carullo, Roberto Bordonaro, Giuseppe Aprile, Alberto Zaniboni, Gianluca Masi, Luca Boni, Chiara Cremolini

J Clin Oncol 44(5) 361-369

PMID41505697
PMCIDPMC12879191
DOI10.1200/JCO-25-01337
发表日期2026-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

We report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). We present overall survival (OS) and updated outcomes in the intention-to-treat population. The median follow-up was 60.2 months (IQR, 49.3-70.0). The median OS was 41.1 and 33.3 months for experimental and control groups, respectively (hazard ratio [HR], 0.79 [95% CI, 0.63 to 0.99]; P = .049). OS outcomes favored the experimental group regardless of clinical features. No differences in objective response rate (primary end point; 75%/78%, odds ratio, 0.84 [95% CI, 0.54 to 1.31]; P = .442), early tumor shrinkage rate (P = .954), depth of response (P = .573), no residual tumor resection rate (P = .329), and progression-free survival (HR, 0.95 [95% CI, 0.78 to 1.16]; P = .606) were confirmed. Among patients alive at the time of disease progression, the median postprogression survival was 24.6 and 17.7 months for experimental and control groups, respectively (HR, 0.79 [95% CI, 0.62 to 1.01]; P = .062). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC.

KM 提取结果

4 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

FIG 2. Kaplan-Meier estimates of OS in the intention-to-treat population, according to treatment groups (A). Forest plot of treatment effect on OS within main clinical and molecular subgroups (B). The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; MMR, mismatch repair; OS, overall survival.

A

OS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG A1.

FIG A1. Kaplan-Meier estimates of PFS in the intention-to-treat population, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; PFS, progression-free survival.

PFS

PFS

FIG A1. · Panel PFS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel PFS 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG A2.

FIG A2. Kaplan-Meier estimates of RFS (A) and postresection OS (B) in patients who underwent secondary R0 surgery, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; NE, not estimable; OS, overall survival; R0, no residual tumor; RFS, relapse-free survival.

A

RFS

FIG A2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG A2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIG A3.

FIG A3. Kaplan-Meier estimates of PPS in the intention-to-treat population, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; PPS, postprogression survival.

Kaplan-Meier_estimates_of_PPS_in_the_intention-to-treat_population

PPS

FIG A3. · Panel Kaplan-Meier_estimates_of_PPS_in_the_intention-to-treat_population

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan-Meier_estimates_of_PPS_in_the_intention-to-treat_population 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. a Patients included in intention-to-treat population. b Patients included in the safety population. c Three patients in the control group and nine patients in the experimental group died on the same day as they had disease progression and were not included in the population for the analysis of PPS. FOLFOX, fluorouracil, leucovorin, oxaliplatin; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; PPS, postprogression survival.
非 KM Figure
FIG 3.FIG 3. Treatments received after disease progression to first-line therapy. Funnel plot in the control group (A) and experimental group (B). Percentages on the left are calculated as the number of patients receiving second, third, and fourth line of therapy relative to the total of enrolled subjects in each treatment group. Percentages on the right are calculated as the number of patients receiving second, third, and fourth line of therapy relative to the total of subjects alive at the time of first, second, and third disease progression, respectively, in each treatment group. Sankey plot depicting the percentage of patients receiving different systemic treatments across subsequent lines of therapy in the control group (C) and experimental group (D). EGFR, epidermal growth factor receptor; FOLFOX, fluorouracil, leucovorin, oxaliplatin; FTP/TPI, trifluridine/tipiracil; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; PD, progression disease; VEGF, vascular endothelial growth factor.
非 KM Figure